UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 21, 2025
Actuate Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-42139 | 47-3044785 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 1751 River Run, Suite 400 Fort Worth, Texas |
76107 |
| (Address of Principal Executive Offices) | (Zip Code) |
(817) 887-8455
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.000001 per share | ACTU | The Nasdaq Stock Market LLC | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Information.
Actuate Therapeutics Disclosure Channels to Disseminate Information
Actuate Therapeutics’ investors and others should note that we announce material information to the public about our company and its technologies, clinical and corporate developments, and other matters through a variety of means, including Actuate Therapeutics’ website, press releases, SEC filings, and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in the locations below as such information could be deemed to be material information. Please note that this list may be updated from time to time.
Interested in keeping up with Actuate Therapeutics?
For more information on Actuate Therapeutics and its technology, clinical and corporate developments, and other matters, please visit: https://actuatetherapeutics.com.
For more information for Actuate Therapeutics’ investors, including press releases, SEC filings, corporate presentations, events, please visit: https://actuatetherapeutics.com/investors. Investors and other interested parties can subscribe to our press releases and SEC filings at the aforementioned address.
For additional information, please follow Actuate Therapeutics social media accounts at:
X account (formerly Twitter): @ActuateThera or https://x.com/ActuateThera
LinkedIn: https://www.linkedin.com/company/actuate-therapeutics-inc./
Facebook profile: https://www.facebook.com/profile.php?id=61572431561095
Investors and other interested parties can also subscribe to our social media accounts at the aforementioned addresses.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Actuate Therapeutics, Inc. | ||
| Date: November 21, 2025 | By: | /s/ Daniel M. Schmitt |
| Name: Daniel M. Schmitt | ||
| Title: President and Chief Executive Officer | ||
| 3 |